Improving quality control in PET drug manufacturing.
Official title: Broad Implementation of a universal solution for quality control modernization in PET radio-pharmaceutical manufacturing industry.
Funded at Trace-Ability, INC. · NIH-10675471 · Data updated 2026-11-12
This study is working to make it easier and faster to produce important PET drugs used in medical imaging, so that patients can get the tests they need without delays.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Trace-Ability, INC. NIH-funded |
| Lab location | 1 site (Van Nuys, United States) |
| Project start | September 1, 2020 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $1,000,000 |
| NIH project number | 5U01FD006957-04 |
| Project ID | NIH-10675471 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients requiring diagnostic imaging that utilizes PET drugs would be ideal candidates to benefit from this research.
✕Less likely to help
Patients who do not require PET imaging or those whose conditions are not addressed by PET drugs may not benefit from this research.
What this research studies
This project aims to enhance the production of PET drugs, which are crucial for diagnostic imaging in various medical conditions. By modernizing the quality control processes, the research seeks to overcome current challenges in throughput and regulatory compliance faced by PET drug manufacturers. The approach involves expanding a previously successful solution, Tracer-QC, to accommodate a wider range of PET drugs, thereby streamlining the manufacturing process and ensuring consistent quality. This could lead to more efficient production and availability of essential imaging products for patients.
Why it matters
Potential benefit: If successful, this research could lead to improved access to a wider variety of high-quality PET imaging products for patients.
How similar studies have gone: Previous research has shown success with the Tracer-QC solution for a specific PET tracer, indicating potential for broader application in the industry.
Where this research is happening
-
Trace-Ability, INC.
Van Nuys, United States Active
Researchers
- Principal investigator: Elizarov, Arkadij — Trace-Ability, INC.
- Study coordinator: Elizarov, Arkadij
Related research
Other NIH-funded projects on the same topics.
-
Automated, GMP-compliant HIV ImmunoPET tracer production for broader clinical use
A new automated system will make HIV-imaging tracers quickly and safely in more clinics, so more people could benefit from ImmunoPET scans.
-
Improving access to Alzheimer’s PET imaging for better clinical trials.
This study is working on making a special type of brain scan for Alzheimer’s disease easier and quicker to produce, so that more patients can get the help they need and researchers can run better clinical trials.
-
Making HIV imaging more accessible through automated production of imaging agents.
This study is working on making a new imaging technique for HIV easier and more affordable for hospitals to use, so that more patients can get better diagnoses and treatment options.
-
Improving the production of components for PET imaging in cancer patients.
This study is working on a new way to make special plates used in PET scans, which help doctors diagnose and treat cancer, so that they can produce them more reliably and safely for patients like you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.